Hsbc Holdings PLC Boosts Holdings in Humana Inc. $HUM

Key Points

• Hsbc Holdings PLC increased its stake in Humana Inc. by 1.8%, owning approximately 0.19% of the company, which is valued at about $61.9 million.
• A record 92.38% of Humana's stock is held by institutional investors, with notable recent changes including First Trust Advisors increasing their holdings by 78.6% in the fourth quarter.
• Analysts have mixed views on Humana's stock, with target prices ranging from $272.00 to $348.00 and an average rating of "Hold" with a target price of $283.29.

Hsbc Holdings PLC increased its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 1.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 234,278 shares of the insurance provider's stock after purchasing an additional 4,219 shares during the quarter. Hsbc Holdings PLC owned 0.19% of Humana worth $61,899,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after purchasing an additional 46 shares during the period. Riverview Trust Co acquired a new position in shares of Humana during the 1st quarter worth $34,000. Garde Capital Inc. purchased a new stake in shares of Humana in the 1st quarter worth about $36,000. Zions Bancorporation National Association UT purchased a new stake in shares of Humana in the 1st quarter worth about $37,000. Finally, Whipplewood Advisors LLC boosted its position in shares of Humana by 639.1% in the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after buying an additional 147 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

Humana stock traded up $1.83 during midday trading on Tuesday, reaching $299.03. 489,977 shares of the company were exchanged, compared to its average volume of 1,714,540. The company has a market capitalization of $35.96 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 1.76 and a beta of 0.44. The firm's 50-day simple moving average is $249.83 and its 200-day simple moving average is $253.46. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $382.72. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. On average, analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.2%. Humana's payout ratio is 27.17%.

Wall Street Analysts Forecast Growth

HUM has been the topic of several recent research reports. Piper Sandler decreased their price objective on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research report on Thursday, July 31st. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a research report on Thursday, May 1st. Morgan Stanley decreased their price objective on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. Finally, Robert W. Baird decreased their price objective on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Seven equities research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Humana has a consensus rating of "Hold" and an average target price of $283.29.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.